Shots:
Alnylam Pharmaceuticals & Inceptive Nucleics have entered into a strategic collaboration to accelerate the discovery of novel RNAi therapeutics
The collaboration is valued at up to $2B, with $30M upfront, incl. cash & an equity investment in Inceptive. Inceptive will also receive additional preclinical, regulatory, & commercial milestone payments
Collaboration combines Alnylam’s RNAi expertise…
